Atea Pharmaceuticals, Inc. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Atea Pharmaceuticals, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-03-31 was $132.00K, a 4.35% decline year-over-year.
- Atea Pharmaceuticals, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-09-30 was $63.00K, a 46.15% decline year-over-year.
- Atea Pharmaceuticals, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-03-31 was $138.00K, a 8.00% decline year-over-year.
- Atea Pharmaceuticals, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-09-30 was $117.00K, a 27.17% increase year-over-year.
- Atea Pharmaceuticals, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $201.00K, a 24.72% decline from fiscal 2024.
- Atea Pharmaceuticals, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $267.00K, a 3.89% increase from fiscal 2023.
- Atea Pharmaceuticals, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $257.00K, a 83.57% increase from fiscal 2022.
- Atea Pharmaceuticals, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $140.00K.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-03-31 | $132.00K 10-Q · filed 2026-08-12 | |
| 2025-12-31 | $201.00K 10-K · filed 2026-03-05 | |
| 2025-09-30 | $63.00K 10-Q · filed 2025-11-12 | |
| 2025-03-31 | $138.00K 10-Q · filed 2026-08-12 | |
| 2024-12-31 | $267.00K 10-K · filed 2026-03-05 | |
| 2024-09-30 | $117.00K 10-Q · filed 2024-11-07 | |
| 2024-03-31 | $150.00K 10-Q · filed 2025-11-12 | |
| 2023-12-31 | $257.00K 10-K · filed 2025-03-06 | |
| 2023-09-30 | $92.00K 10-Q · filed 2024-11-07 | |
| 2023-03-31 | $165.00K 10-Q · filed 2024-11-07 | |
| 2022-12-31 | $140.00K 10-K · filed 2024-02-28 | |
| 2022-09-30 | $140.00K 10-Q · filed 2023-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |